Eli Lilly became the first U.S. pharmaceutical firm to exceed a $1 trillion market capitalization.
Eli Lilly passed the $1 trillion valuation threshold in 2024 as investors responded to strong demand and expectations for its diabetes and obesity medicines. The company’s market value was supported particularly by Mounjaro and Zepbound, which contain the active ingredient tirzepatide and are used for different approved indications.
The company was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Union veteran. Lilly emphasized the production of medicines with consistent quality, an important issue in an era when drug composition could vary substantially.
Market capitalization measures the value investors assign to outstanding shares; it is not a measure of annual drug sales or the amount patients pay. Lilly’s valuation can change with clinical-trial results, regulatory decisions, competition, supply capacity, and changing expectations about future medicine demand.